Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.39 |
| ▸ | MMP3 | P08254 | 6/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 4/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290067 | 0.89 | MMP2 (0.41) | MMP2MMP3MMP1MGLLFKBP1A | |
| SCHEMBL7840445 | 0.83 | MMP1 (0.46) | MMP2MMP3MMP1 | |
| SCHEMBL7423731 | 0.82 | MGLL (0.39) | MMP2MMP3MGLLFKBP1A | |
| SCHEMBL6983815 | 0.79 | MMP1 (0.41) | MMP2MMP3CCNA2CDK2CCNA1 | |
| SCHEMBL7411014 | 0.78 | CCNA2 (0.35) | MMP2MMP3CCNA2CDK2CCNA1 | |
| SCHEMBL4287736 | 0.78 | EPHX2 (0.40) | MMP2MMP3MGLLFKBP1A | |
| SCHEMBL7383416 | 0.77 | REN (0.39) | MMP2MMP3CCNA2CDK2CCNA1 | |
| SCHEMBL6942326 | 0.77 | MMP1 (0.39) | MMP2MMP3MMP1REN | |
| SCHEMBL7840440 | 0.77 | LMNA (0.40) | MMP2MMP3MMP1MGLL | |
| SCHEMBL6986871 | 0.76 | MMP1 (0.37) | MMP2MMP3MMP1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |
| WO-2000012082-A1 | FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |